Skip to main content

From the helm: Immutep’s (ASX:IMM) Executive Director & CEO, Marc Voigt

Jessica Amir
August 26, 2021

In this instalment of our From the helm series, Bell Direct’s Jessica Amir speaks to Immutep’s (ASX:IMM) Executive Director and CEO, Marc Voigt.

Immutep has gained a lot of attention, as its trials in collaboration with big-names, Pfizer and Merck, has seen a remission in patients’ tumours. Between capital raisings and partnerships, Immutep continues to deliver impressive results…

In this video Marc discusses:

  • (0:40) IMM’s progress: the year that was, and the year ahead
  • (1:30) Promising results from an IMM study in collaboration with Pfizer and Merck
  • (2:29) Its unique discovery in immunotherapy – which spells new opportunities
  • (4:02) Key catalysts that could drive share price growth
  • (6:00) Fund managers who bought into IMM recently – and how funds raised will be spent

How to open an account

Bell Direct
September 1, 2015

Beston Global Food Company Interview

Bell Direct
August 28, 2015

Bell Direct Insights: Richard Hemming

Bell Direct
August 24, 2015

Bell Potter video: Bank sector update

Bell Direct
August 14, 2015

Agricultural Sector Review

Bell Direct
August 3, 2015

Peter Quinton: three REITs

Bell Direct
July 23, 2015

Contango CIO interview

Bell Direct
July 17, 2015

Julia Lee on mFunds

Bell Direct
July 6, 2015